difelikefalin: Clinical Trials

6 trials of difelikefalin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 terminated, 1 recruiting. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Terminated 2, Recruiting 1
Phase 31Terminated 1

Follow difelikefalin: new trials by email Literature Review of difelikefalin trials Research Report on difelikefalin

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Difelikefalin - Pruritus, Chronic Kidney Diseases
Phase 2RecruitingVifor Fresenius Medical Care Renal Pharma182026-08-042026-10-23
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica
difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets - Pruritus, Notalgia Paresthetica
Phase 2 / Phase 3TerminatedCara Therapeutics, Inc.2142023-08-012024-06-21
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
difelikefalin 2.0 mg, Placebo - Pruritus, Notalgia Paresthetica
Phase 2CompletedCara Therapeutics, Inc.1262021-01-112023-05-22
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg - Pruritus, Atopic Dermatitis
Phase 2CompletedCara Therapeutics, Inc.4012019-06-292022-04-04
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
CR845 1.0 mg, Placebo - Cholestatic Pruritus
Phase 2TerminatedCara Therapeutics, Inc.142019-06-252023-07-03
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet - Chronic Kidney Diseases, Pruritus
Phase 2CompletedCara Therapeutics, Inc.2692018-07-052024-01-24

Conditions studied

Pruritus (6)  ·  Renal Insufficiency, Chronic (2)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Kidney Failure, Chronic (1)  ·  Liver Cirrhosis, Biliary (1)

Sponsors

Cara Therapeutics, Inc. (5)  ·  Vifor Fresenius Medical Care Renal Pharma (1)

Countries

United States (5)  ·  Canada (3)  ·  Spain (2)  ·  China (1)  ·  Germany (1)  ·  Greece (1)  ·  Israel (1)  ·  Poland (1)  ·  Saudi Arabia (1)  ·  United Arab Emirates (1)  ·  United Kingdom (1)

Top investigators

Kristine Nograles (1)  ·  Nilam Shah (1)

Results publications

PMID 36780675

NIH funding

2023 (1)